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Phosphofructokinase deficiency is a very rare autosomal recessive disorder, which belongs
to group of rare inborn errors of metabolism called glycogen storage disease. Here we
report on a new mutation in the phosphofructokinase (PFK) gene PFKM identified in a
65-years-old woman who suffered from lifelong intermittent muscle weakness and painful
spasms of random occurrence, episodic dark urines, and slight haemolytic anemia. After
ruling out the most common causes of chronic haemolytic anemia, the study of a panel of
24 enzyme activities showed a markedly decreased PFK activity in red blood cells (RBCs)
from the patient. DNA sequence analysis of the PFKM gene subsequently revealed a novel
homozygous mutation: c.926A>G; p.Asp309Gly. This mutation is predicted to severely
affect enzyme catalysis thereby accounting for the observed enzyme deficiency. This case
represents a prime example of classical PFK deficiency and is the first reported case of
this very rare red blood cell disorder in Spain.
Keywords: phosphofructokinase deficiency, glycogen storage disease, PFKM gene, missense mutation, enzyme
catalysis
INTRODUCTION
Phosphofructokinase (ATP: D- fructose-6-phosphate-1-
phosphotransferase; EC 2.7.1.11; PFK) is a key regulatory
enzyme of the glycolytic cycle and catalyses the conversion of
fructose-6-phosphate to fructose-1,6-diphosphate (Figure 1).
Human PFK is composed of three isoenzymes, muscle (M), liver
(L), and platelet (P) (Vora, 1983; Nakajima et al., 2002). The P
type is also known as Fibroblast type (F). Mammalian PFK is
a tetrameric enzyme that is subjected to allosteric regulation.
Tissue isozymes randomly aggregate to form homotetramers
or heterotetramers depending on the relative abundance of the
subunits in a particular tissue. PFK-M is the sole subunit in
muscle cells whereas red blood cells (RBCs) contain both L
andM subunits and form their hybrids (M4, L4, M3L, M2L2,
and ML3).
Phosphofructokinase deficiency (OMIM 171 850) is a very
rare autosomal recessive condition with heterogeneous clinical
symptoms, mainly characterized by myopathy and/or haemolysis
(Hirano and Di Mauro, 1999). Myopathy is caused by the accu-
mulation of glycogen in muscle tissue due to the metabolic defect
and is also known as glycogenosis type VII or Tarui disease. It is
characterized by muscle pain, exercise-induced fatigue, cramps,
and myoglobinuria. The observed clinical symptoms reflect lack
of muscle PFK activity and partial reduction of enzymatic activ-
ity in erythrocytes. The latter usually is associated with mild
haemolysis.
Up to now, only about 100 patients with PFK deficiency have
been reported worldwide and 22 PFK-deficient PFKM alleles have
been characterized. The gene encoding theM subunit (PFKM)
has been assigned to chromosome 12q13.3 and spans 30 kb. It
contains 24 exons and at least 3 promoter regions (Elson et al.,
1990; Yamada et al., 2004). Among the detected mutations are
mostly missense mutations and splicing defects.
We now describe here a Spanish patient with a clinical his-
tory of anemia, haemolysis, and intermittent muscle weakness,
who was found to be homozygous for a novel mutation in the
PFKM gene (c.926A>G). This mutation encodes the substitution
of aspartic acid by glycine at residue 309 (p.Asp309Gly). This is
the first description of PFK deficiency in Spain.
CASE REPORT
A 65-years-old woman with long standing hypertension and type
2 diabetes was referred to our Unit because of intolerance to exer-
cise and chronic fatigue. From youth she suffered from spasms
of random occurrence associated with muscle weakness, painful
intolerance to small efforts, and intermittent dark urines, espe-
cially after exercise due to myoglobinuria, as revealed by urinaly-
sis. Physical examination showed no weakness or muscle atrophy
and only amoderate splenomegaly without hepatomegaly or lym-
phadenopathy. Parents were unavailable for study and there was
no known consanguinity. The same clinical picture, however,
was present in a non-smoker brother whereas the three patient’s
daughters were normal. Patient’s clinical condition has remained
stable in follow-up.
Complete blood count (CBC) showed moderate anemia
(Hb: 115 g/L), with slight macrocytosis (105 fl) and increased
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FIGURE 1 | Embden Meyerhof Pathway of RBC metabolism. Phosphofructokinase (PFK) catalyzes the transformation of fructose 6-phosphate into fructose
1,6 diphosphate. [Reproduced with permission from Van Wijk and van Solinge (2005)]
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number of circulating reticulocytes (110× 109/L). Leukocyte
and platelet counts, as well as general serum biochemical anal-
ysis, were within normal range, except for a moderate rise
in non-conjugated bilirubin, lactate dehydrogenase (LDH) and
uric acid (hyperuricemia). Biological signs of diabetes melli-
tus type 2 were also present. The studies performed to rule
out the origin of the anemia, discarded nutritional deficiencies
(serum iron tests, cobalamin and serum folate were all nor-
mal), haemoglobinopathies (HPLC and thermal stability), and
paroxysmal nocturnal haemoglobinuria (normal flow cytome-
try measurement of CD45 and CD49 in leukocytes and RBCs).
Hereditary RBCmembrane defects were ruled out bymorpholog-
ical observation of May-Grünwald-Giemas stained blood smears,
and a normal osmotic fragility test. Extensive study of RBC
enzyme activity measurements demonstrated a marked decrease
(<30% of normal) in PFK activity (Table 1). DNA sequence anal-
ysis of individual exons of PFKM, including flanking splice sites,
revealed that the patient was homozygous for a missense muta-
tion in exon 11: c.929A>G. This mutation, that has not been
previously reported in the literature, encodes the substitution of
aspartic acid by glycine at residue 309 (p.Asp309Gly). Mutation
prediction programs PolyPhen-2 (Adzhubei et al., 2010) and SIFT
(Kumar et al., 2009) predict this mutation to be pathogenic (i.e.,
disease causing).
The complete lack of PFK activity in muscle was confirmed
on both histological preparations and muscle extracts. Muscle
abnormality was also confirmed by electromyography (EMG),
that showed mild myopathic changes and by the forearm test,
characterized by a plane lactate curve with normal increase of
ammonium. As usual in patients with glycogenosis, a painful
spasm occurred at the end of the forearm test. Muscle biopsy
showed slight amounts of polysaccharide (PAS) not digested by
diastase and abnormalities in NADH-TR reaction.
DISCUSSION
In this report, we describe, for the first time, the occurrence of
PFK deficiency in Spain in an adult woman of 65 years of age. Her
moderate haemolysis was associated with the accumulation of
muscle glycogen comparable to that of Tarui disease. Muscle pain
and exercise-induced fatigue and weakness associated with dark
urines were the most relevant clinical manifestations. She was
found to be homozygous for a novel missense mutation in PFKM,
the gene that encodes the PFK-M subunit. On the amino acid
level, this mutation (c.929A>G) causes the substitution of aspar-
tic acid by glycine at residue 309. Asp309 is part of an α-helix, and
Table 1 | Red blood cell enzyme activity measurements.
Patient Reference value
G6PD activity (IU/g Hb) 7.0 6.2–9.9
HK activity (IU/g Hb) 1.2 0.6–1.3
PGI activity (IU/g Hb) 61.9 46.0–66.0
PK activity (IU/g Hb) 15.3 9.5–15.6
PFK activity (IU/g Hb) 3.07 6.4–13.9
Glucose-6-phosphate dehydrogenase; HK, Hexokinase; PGI, Phosphoglucose
isomerase; PK, Pyruvate kinase; PFK, Phosphofructokinase.
replacement with glycine could disrupt this α-helix. Furthermore,
structural analysis using the 3D molecular model of rabbit mus-
cle type PFK (PDB entry 3O8L) showed that the p.Asp309Gly
substitution is located in direct vicinity of the nucleotide (ADP)
binding site in the center of the PFKM subunit (Figure 2A). PFK
is allosterically activated by ADP, and the ADP binding site has
been recently identified (Banaszak et al., 2011). Asp309 does not
directly interact with ADP, however, substitution of Asp309 by
glycine is likely to disrupt multiple hydrogen bonds with Gly177,
Gly179, Ser 180, and Ser306 (Figure 2B). This loss of hydrogen
bonds and the change of polarity and electrostatic interactions
upon mutation of Asp309 will likely affect correct positioning of
the side-chains of amino acids directly involved in ADP bind-
ing (Figure 2B), in particular neighboring residue Phe308, which
makes stacking interaction with the adenine ring of ADP. This
hypothesis is further supported by recent functional studies of
the Asp543Ala change in PFKM. This mutation is associated with
Tarui disease, and substitution of Asp543 by Ala was shown to dis-
rupt hydrogen bonds with ADP (Brüser et al., 2012). We therefore
postulate that decreased binding of the allosteric activator ADP
will inhibit PFK enzymatic activity, in particular under low energy
levels. These findings support the physiological importance of
Asp390 for the recently identified ADP binding site.
The missense mutation is thus predicted to lead to a less func-
tional PFK-M subunit. In accordance with this, the complete lack
of PFK activity in muscle was confirmed on both histological
preparations and muscle extracts. The muscle abnormality was
also confirmed by electromyography, ischemic exercise testing,
histochemistry and electron microscopy. Furthermore, partial
red blood cell PFK deficiency was reflected by the moderately
decreased enzymatic activity in red blood cells, leading to mild
haemolytic anemia
PFK is a key regulatory enzyme for glycolysis (Van Wijk and
van Solinge, 2005) and catalyzes the irreversible transfer of phos-
phoryl from ATP to fructose-6-phosphate, and converts it to
fructose-1,6-bisphosphate. Thus, tissues deficient in PFK cannot
use free or glycogen-derived glucose as a fuel source and accu-
mulate glycogen (glycogenosis). PFK deficiency (Tarui disease)
was the first disorder recognized to directly affect glycolysis (Tarui
et al., 1965). Since this first description of the disease, a wide range
of biochemical, physiological and molecular studies have greatly
contributed to our knowledge concerning not only PFK function
in normal muscle, but also on the general control of glycolysis
and glycogen metabolism. So far, more than one 100 patients
have been described with prominent clinical symptoms charac-
terized by muscle cramps, exercise intolerance, rhabdomyolysis
and myoglobinuria, often associated with haemolytic anemia and
hyperuricemia. In classic Tarui disease, the genetic defect involves
theM isoform, resulting in the absence of enzymatic activity in
the muscle. Erythrocytes lack the M4 and hybrid isozymes and
only express the L4 homotetramers, resulting in about 50% of
normal PFK activity (Figure 3). Thus, haemolysis is a result of
partial erythrocyte PFK deficiency.
Despite PFK deficiency is a very rare autosomal recessive dis-
ease; its true incidencemay be higher due to lack of recognition, as
symptoms may be quite mild. In fact, our case highlights the lat-
ter, because the mild clinical presentation led her to be diagnosed,
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FIGURE 2 | 3D crystal structure of PFK subunit from rabbit skeletal
muscle and 3D model of normal/mutated PFKM (PDB 3O8L—protein
databank). (A) Allosteric nucleotide (ADP) binding site residues (purple) in
the center of the rabbit subunit of PFKM, and the allosteric activator ADP are
shown (atom coloring: carbon—green, nitrogen—blue, oxygen—red,
phosphor—orange). (B) Close-up of the c.Asp309Gly mutation in PFKM.
Asp309 is in close proximity of the ADP binding site. Asp309 does not
directly interact with ADP. However, substitution of Asp309 by glycine is likely
to disrupt multiple hydrogen bonds with Gly177, Gly179, Ser 180 and Ser306
(black dotted lines). This loss of hydrogen bonds, and the change of polarity
and electrostatic interactions upon mutation of Asp309 will likely affect
correct positioning of the side-chains of amino acids directly involved in ADP
binding; in particular neighboring residue Phe308, which makes stacking
interaction with the adenine ring of ADP.
for many years, as chronic fatigue, until the consideration of dark
urines ultimately led to the study of chronic haemolysis. In our
case the combination of RBC enzyme activity measurements and
muscle biopsy analysis allowed for the correct diagnosis even at
this late stage of life.
Generally, PFK deficiency presents in childhood. Clinical his-
tory however, defines 4 main subtypes: (1) classic, (2) infan-
tile onset, (3) late onset, and (4) haemolytic. Most of the
reported cases belong to the classic form, characterized by exercise
intolerance, fatigue, muscle cramps with pain and myoglobin-
uria (Hirano and Di Mauro, 1999). A compensated haemolysis
with jaundice, increased serum creatine kinase (CK) and hype-
ruricemia is also commonly present. Sometimes, nausea and
vomiting appear after intense physical efforts Patients with the
infantile onset may manifest as “floppy babies” that die within
the first year of life. Symptoms include myopathy, psychomo-
tor retardation, cataracts, joint contractures, and death during
early childhood. They can also show evidence of arthrogrypo-
sis and mental retardation. Patients with the late-onset form
may present in adulthood with progressive muscle weakness,
cramps and myalgias in later life. Exercise ability, however, is
low already in childhood, and a mild muscle weakness may
appear in the 5th decade leading to severe disability. Diagnosis
depends on patient history, physical examination and the findings
from muscle biopsy, electromyography, ischemic forearm test-
ing, CK testing. RBC enzyme activity measurement is, however,
the easiest way to establish the definitive diagnosis. Fatal infan-
tile type and late-onset forms of PFK clinical expression are
very rare, with only several reported cases. The haemolytic form
presents with hereditary non-spherocytic haemolytic anemia
withoutmusclemanifestations (Fujii andMiwa, 2000). Due to the
molecular genetic heterogeneity, a clear-cut genotype-phenotype
correlation has not been recognized in patients with PFK defi-
ciency (Toscano and Musumeci, 2007). Unfortunately, no spe-
cific treatment or cure of enzyme deficiency exists. Although
diet therapy may be highly effective at reducing clinical man-
ifestations, Tarui disease resolves with rest. Fortunately, the
condition does not progress to severe disability. Because the
liver and kidneys express only the L isoform, these organs are
spared.
About 100 cases of PFK deficiency have been reported in
patients with Tarui disease from Europe, USA,and Japan with
some predominance in Ashkenazi Jews (Fujii and Miwa, 2000).
Up to know, 22 different mutations of PFK have been described.
Missense and splicing mutations are the most frequently occur-
ring mutations in PFKM. Intriguingly, PFK-deficient Ashkenazi
Jews share 2 common mutations in the gene. A splicing defect
caused by the G>A base change at the first nucleotide in intron
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FIGURE 3 | Molecular basis of PFK deficiency. In classic Tarui disease, the
genetic defect involves theM isoform of PFK enzyme, resulting a severe
enzyme deficiency in muscle. Erythrocytes that normally have two
homotetramers (M4 and L4) and three hybrid isozymes (M3L, M2L2 and
ML3), lack the M4 isoform and the hybrid isozymes, and only express the L4
homotetramers, resulting in about 50% of normal PFK activity
5 (c.237+1G>A) accounts for 68% of mutant Ashkenazi alleles,
and a single base deletion in exon 22 (c.2003delC) accounts for
about 27% of mutant Ashkenazi alleles (Raben and Sherman,
1995). The here described homozygous patient is the first Spanish
case described to be affected by this very rare disease. The iden-
tification of a novel homozygous missense mutation further
extends the repertoire of PFK deficiency-associated mutations in
PFKM.
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